KYKOF News and Press, Kyowa Hakko Kogyo From 12/15/20

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company focused on a 2-product pipeline including SNDX-5613, a Menin inhibitor for MLLR/NPM1, and SNDX-6352, a monoclonal antibody for GVHD. Syndax has a pipeline of 3 therapeutics (SNDX-5613, SNDX-6352, Entinostat) with 2 s...

The European commission has approved Kyowa Kirin' (KYKOF) Crysvita (burosumab) for use in older adolescents and adults patients with rare disease X-linked hypophosphataemia ((XLH)), an inherited disorder characterized by low levels of phosphate in the blood leading to soft and weak ...

Kyowa Kirin (KYKOF) and MEI Pharma (MEIP) have dosed the first patient in Phase 2 study of zandelisib (ME-401) for the treatment of indolent B-cell non-Hodgkin's lymphoma (iNHL) without small lymphocytic lymphoma, lymphoplasmacytic lymphoma, and Waldenström's macroglobulinemia in&#x...

MEI Pharma (NASDAQ: MEIP ) jumps  77%  premarket on robust volume in reaction to its agreement with Kyowa Kirin Co., Ltd. ( OTCPK:KYKOF ) to co-develop and co-promote Phase 2-stage ME-401 in the U.S. for the treatment of B-cell blood cancers. More news on: MEI Pharma, Inc., Kyo...

Ultragenyx (NASDAQ: RARE ) and collaboration partner Kyowa Kirin ( OTCPK:KYKOF ) announce the filing of a supplemental marketing application in the U.S. seeking approval to use Crysvita (burosumab) to treat FGF23-related hypophosphatemia associated with phosphaturic mesenchymal tumors (tum...

TOKYO , Jan. 6, 2020 /PRNewswire/ -- Kyowa Kirin Co., Ltd. (TSE: 4151) President and CEO: Masashi Miyamoto , "Kyowa Kirin") today announces that its marketing authorisation application (MAA) for istradefylline (KW-6002) as an adjunctive treatment to levodopa-based regimens in adult patie...

Ardelyx (NASDAQ: ARDX ) +9.1% after-hours on news it is expanding its partnership with Kyowa Kirin ( OTCPK:KYKOF ) through two new agreements and receiving a $20M equity investment from the Japanese biopharma company. More news on: Ardelyx, Inc., Kyowa Kirin Co., Ltd., Healthcare stock...

Ultragenyx (NASDAQ: RARE ) and collaboration partner Kyowa Kirin ( OTCPK:KYKOF ) announce  plans to submit a supplemental marketing application to the FDA in H1 2020 seeking approval to use Crysvita (burosumab) to treat FGF23-related hypophosphatemia associated with phosphaturic mesenc...

Mitsubishi Tanabe Pharma America ( OTCPK:MTZPY -1.5% ) initiates a Phase 3 clinical trial, BouNDless , evaluating continuous subcutaneously administered carbidopa/levodopa (ND0612) compared to the oral formulation in Parkinson's disease (PD) patients. More news on: Mitsubishi Tanabe P...

The FDA approves Kyowa Kirin's ( OTCPK:KYKOF ) Nourianz (istradefylline) tablets as an add-on treatment to levodopa/carbidopa for adults with Parkinson's disease (PD) who are experiencing "off" episodes. More news on: Kyowa Kirin Co., Ltd., Healthcare stocks news, Read more ...